Resminostat for maintenance treatment of patients with advanced stage mycosis fungoides or Sézary syndrome

Resminostat is in clinical development for the maintenance treatment of adults with mycosis fungoides (MF) and Sézary syndrome (SS) which are the most common types of cutaneous T-cell lymphoma (CTCL), a rare type of non-Hodgkin lymphoma affecting the skin. CTCL can develop when T-cells become abnormal. T-cells are one of the important types of white blood cells in the immune system and play a central role in the adaptive immune response. MF is usually a very slow-growing type of lymphoma that primarily affects the skin. It arises from malignant T-cells that infiltrate the top two layers of the skin (epidermis and dermis). SS usually grows faster and involves the uncontrolled growth of cancerous T-cells that spread through the bloodstream. CTCL may cause skin changes, including rash-like patches, itchy and sometimes painful areas, plaques, and lumps. MF and SS are often challenging to manage due to the lack of reliably curative therapies and the necessity for ongoing treatment and symptom control.